Literature DB >> 12588205

Acute myocardial infarction in human immunodeficiency virus-infected patients.

Shlomo Matetzky1, Michelle Domingo, Saibal Kar, Marko Noc, Prediman K Shah, Sanjay Kaul, Eric Daar, Bojan Cercek.   

Abstract

BACKGROUND: Patients infected with human immunodeficiency virus (HIV) are at an increased risk for premature coronary artery disease. However, the clinical outcome of HIV-infected patients who have had an acute myocardial infarction (AMI) is unknown.
METHODS: We studied 24 consecutive HIV-infected patients admitted because of AMI. During the hospital phase, the patients were examined for recurrent ischemia, congestive heart failure, arrhythmia, and death. Patients were followed up for an average of 15 months after discharge for reinfarction; recurrent angina; the need for any angioplasty, bypass surgery, or target vessel revascularization for restenosis and stent thrombosis; HIV-related complications; and death. For comparison, we included a matched control group of non-HIV-infected patients.
RESULTS: The HIV-infected patients with AMI were predominantly male (21 [88%]), 47 +/- 9 years of age. Twenty-two (92%) were receiving antiretroviral treatment; 17 (71%), protease inhibitors; and 13 (54%), lipid-lowering therapy. With aggressive therapy, the lipid profile was similar in HIV-infected patients treated with protease inhibitors and those who were not. Twenty-one (88%) of 24 patients underwent immediate angiography and 20 (83%) had angioplasty or bypass surgery. The HIV-infected patients with AMI had a benign in-hospital course, with no deaths or reinfarction. The admission characteristics, treatment strategy, and in-hospital outcome were similar in the matched uninfected patients with AMI. After discharge, HIV-infected patients had a higher incidence of reinfarction (4/20 [20%] vs 2/45 [4%]; P =.07), and 6 (43%) of 14 HIV-infected patients who had successful percutaneous coronary intervention and were available for follow-up required target vessel revascularization compared with 4 (11%) of 38 uninfected patients who had successful percutaneous coronary intervention and were available for follow-up (P =.02).
CONCLUSIONS: Patients infected with HIV sustain AMI at a young age and have a benign in-hospital course. Although HIV-infected patients have a higher incidence of postdischarge ischemic events, restenosis, and stent thrombosis, the intermediate-term mortality is low.

Entities:  

Mesh:

Year:  2003        PMID: 12588205     DOI: 10.1001/archinte.163.4.457

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  22 in total

1.  Percutaneous coronary intervention in HIV infected patients: immediate results and long term prognosis.

Authors:  F Boccara; E Teiger; A Cohen; S Ederhy; S Janower; G Odi; E Di Angelantonio; G Barbarini; G Barbaro
Journal:  Heart       Date:  2006-04       Impact factor: 5.994

2.  Acute Coronary Syndrome In HIV Naïve Patient With Low CD4 Count And No Other Significant Risk Factors: Case Report And Literature Review.

Authors:  Zaher Fanari; Sumaya Hammami; Muhammad Baraa Hammami; William S Weintraub; Wasif A Qureshi
Journal:  Open J Clin Med Case Rep       Date:  2015

Review 3.  HIV infection and coronary heart disease: mechanisms and management.

Authors:  Priscilla Y Hsue; David D Waters
Journal:  Nat Rev Cardiol       Date:  2019-06-10       Impact factor: 32.419

Review 4.  Accelerated aging and human immunodeficiency virus infection: emerging challenges of growing older in the era of successful antiretroviral therapy.

Authors:  Ramona Bhatia; Patrick Ryscavage; Babafemi Taiwo
Journal:  J Neurovirol       Date:  2011-12-29       Impact factor: 2.643

Review 5.  Coronary heart disease in HIV-infected patients.

Authors:  Marshall J Glesby
Journal:  Curr HIV/AIDS Rep       Date:  2005-06       Impact factor: 5.071

Review 6.  Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy.

Authors:  Fabrizio D'Ascenzo; Enrico Cerrato; Giuseppe Biondi-Zoccai; Claudio Moretti; Pierluigi Omedè; Filippo Sciuto; Mario Bollati; Maria Grazia Modena; Fiorenzo Gaita; Imad Sheiban
Journal:  Eur Heart J       Date:  2011-12-20       Impact factor: 29.983

7.  Recurrence after hospitalization for acute coronary syndrome among HIV-infected and HIV-uninfected individuals.

Authors:  J L Marcus; L B Hurley; A Prasad; J Zaroff; D B Klein; M A Horberg; A S Go; G N DeLorenze; C P Quesenberry; S Sidney; J C Lo; M J Silverberg
Journal:  HIV Med       Date:  2018-09-04       Impact factor: 3.180

Review 8.  Acute coronary syndrome in HIV patients: from pathophysiology to clinical practice.

Authors:  Enrico Cerrato; Fabrizio D'Ascenzo; Giuseppe Biondi-Zoccai; Pierluigi Omedè; Claudio Moretti; Stefania Cicalini; Gurumurthy Parthasarathi; Imad Sheiban; Fiorenzo Gaita
Journal:  Cardiovasc Diagn Ther       Date:  2012-03

9.  Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites.

Authors:  Niloufar Marsousi; Youssef Daali; Pierre Fontana; Jean-Luc Reny; Virginie Ancrenaz-Sirot; Alexandra Calmy; Serge Rudaz; Jules Alexandre Desmeules; Caroline Flora Samer
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

10.  The Relationship Between HIV Infection and Cardiovascular Disease.

Authors:  Birgitt Dau; Mark Holodniy
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.